

# Rena M Conti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4401912/publications.pdf>

Version: 2024-02-01

96  
papers

3,992  
citations

236612

25  
h-index

123241

61  
g-index

97  
all docs

97  
docs citations

97  
times ranked

4966  
citing authors

#	ARTICLE	IF	CITATIONS
1	Naloxone and Buprenorphine Prescribing Following US Emergency Department Visits for Suspected Opioid Overdose: August 2019 to April 2021. <i>Annals of Emergency Medicine</i> , 2022, 79, 225-236.	0.3	18
2	US Insurer Spending on Ivermectin Prescriptions for COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 584.	3.8	17
3	Trends in and Factors Associated With Out-of-Pocket Spending for COVID-19 Hospitalizations From March 2020 to March 2021. <i>JAMA Network Open</i> , 2022, 5, e2148237.	2.8	2
4	Ensuring a high-quality and resilient supply chain of essential medications means paying more. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2022, 28, 573-576.	0.5	1
5	Potential Change in Insulin Out-of-Pocket Spending Under Cost-Sharing Caps Among Pediatric Patients With Type 1 Diabetes. <i>JAMA Pediatrics</i> , 2021, 175, 90.	3.3	3
6	The geography of prescription pharmaceuticals supplied to the USA: levels, trends, and implications. <i>Journal of Law and the Biosciences</i> , 2021, 8, lsa085.	0.8	5
7	Spending For Orphan Indications Among Top-Selling Orphan Drugs Approved To Treat Common Diseases. <i>Health Affairs</i> , 2021, 40, 453-460.	2.5	16
8	Out-of-Pocket Spending for Influenza Hospitalizations in Medicare Advantage. <i>American Journal of Preventive Medicine</i> , 2021, 60, 537-541.	1.6	3
9	Prescription Drug Dispensing to US Children During the COVID-19 Pandemic. <i>Pediatrics</i> , 2021, 148, .	1.0	28
10	Prevalence and Magnitude of Potential Surprise Bills for Childbirth. <i>JAMA Health Forum</i> , 2021, 2, e211460.	1.0	4
11	The cost-effectiveness of therapeutic drug monitoring for the prescription drug-based treatment of chronic myeloid leukemia. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2021, 27, 1077-1085.	0.5	1
12	Opioid Prescribing to US Children and Young Adults in 2019. <i>Pediatrics</i> , 2021, 148, .	1.0	40
13	Projections of US Prescription Drug Spending and Key Policy Implications. <i>JAMA Health Forum</i> , 2021, 2, e201613.	1.0	8
14	Assessment of Out-of-Pocket Spending for COVID-19 Hospitalizations in the US in 2020. <i>JAMA Network Open</i> , 2021, 4, e2129894.	2.8	21
15	Regulating Drug Prices while Increasing Innovation. <i>New England Journal of Medicine</i> , 2021, 385, 1921-1923.	13.9	4
16	Prescriptions for Codeine or Hydrocodone Cough and Cold Medications to US Children and Adolescents Following US Food and Drug Administration Safety Communications. <i>JAMA Network Open</i> , 2021, 4, e2134142.	2.8	6
17	How Do Commercial Insurance Plans Fare Under Proposed Prescription Drug Price Regulation?. <i>JAMA Health Forum</i> , 2021, 2, e214242.	1.0	2
18	Four Facts Concerning Competition in US Generic Prescription Drug Markets. <i>International Journal of the Economics of Business</i> , 2020, 27, 27-48.	1.0	11

#	ARTICLE	IF	CITATIONS
19	ASHP Foundation Pharmacy Forecast 2020: Strategic Planning Advice for Pharmacy Departments in Hospitals and Health Systems. American Journal of Health-System Pharmacy, 2020, 77, 84-112.	0.5	29
20	Association of Opioid Prescribing Patterns With Prescription Opioid Overdose in Adolescents and Young Adults. JAMA Pediatrics, 2020, 174, 141.	3.3	60
21	Trends In Orphan Drug Spending And Out-Of-Pocket Spending Among US Children, 2013â€“18. Health Affairs, 2020, 39, 1806-1811.	2.5	4
22	Policy Implications of the Orphan Drug Designation for Remdesivir to Treat COVID-19. JAMA Internal Medicine, 2020, 180, 1273.	2.6	2
23	60ÂYears after Kefauver: Household income required to buy prescription drugs in the United States and abroad. Research in Social and Administrative Pharmacy, 2020, 17, 1489-1495.	1.5	3
24	Out-of-Pocket Spending for Insulin, Diabetes-Related Supplies, and Other Health Care Services Among Privately Insured US Patients With Type 1 Diabetes. JAMA Internal Medicine, 2020, 180, 1012.	2.6	23
25	How The ACA Reframed The Prescription Drug Market And Set The Stage For Current Reform Efforts. Health Affairs, 2020, 39, 445-452.	2.5	8
26	Pediatric Orphan Drug Indications: 2010â€“2018. Pediatrics, 2020, 145, .	1.0	11
27	Relationship between initiation of 340B participation and hospital safetyâ€net engagement. Health Services Research, 2020, 55, 157-169.	1.0	7
28	Differences in the Receipt of Low-Value Services Between Publicly and Privately Insured Children. Pediatrics, 2020, 145, .	1.0	20
29	Public research funding and pharmaceutical prices: do Americans pay twice for drugs?. F1000Research, 2020, 9, 707.	0.8	4
30	Minimum Travel Distance Among Publicly Insured Infants with Severe Congenital Heart Disease: Potential Impact of In-state Restrictions. Pediatric Cardiology, 2019, 40, 1599-1608.	0.6	11
31	Trends in the Price per Median and Mean Life-Year Gained Among Newly Approved Cancer Therapies 1995 to 2017. Value in Health, 2019, 22, 1387-1395.	0.1	8
32	Revenues and Profits From Medicare Patients in Hospitals Participating in the 340B Drug Discount Program, 2013-2016. JAMA Network Open, 2019, 2, e1914141.	2.8	17
33	Assessment of Prescriber and Pharmacy Shopping Among the Family Members of Patients Prescribed Opioids. JAMA Network Open, 2019, 2, e193673.	2.8	11
34	Pharmacy Benefit Manager Reform. JAMA - Journal of the American Medical Association, 2019, 322, 299.	3.8	5
35	Out-of-pocket Spending on Orphan Drug Prescriptions Among Commercially Insured Adults in 2014. Journal of General Internal Medicine, 2019, 34, 338-340.	1.3	6
36	Appropriately Framing Child Health Care Spending. JAMA - Journal of the American Medical Association, 2018, 319, 1087.	3.8	17

#	ARTICLE	IF	CITATIONS
37	Generic prescription drug price increases: which products will be affected by proposed anti-gouging legislation?. <i>Journal of Pharmaceutical Policy and Practice</i> , 2018, 11, 29.	1.1	9
38	The generic drug user fee amendments: an economic perspective. <i>Journal of Law and the Biosciences</i> , 2018, 5, 103-141.	0.8	7
39	Diversity of Participants in the 340B Drug Pricing Program for US Hospitals. <i>JAMA Internal Medicine</i> , 2018, 178, 1124.	2.6	11
40	Productivity Loss Among Parent Caregivers Is Associated with Poor Health-Related Quality of Life (HRQL) at the Intial Diagnosis of Pediatric Advanced Stage Hodgkin Lymphoma (HL). <i>Blood</i> , 2018, 132, 975-975.	0.6	1
41	Out-of-Pocket Spending Among Commercially Insured Patients for Epinephrine Autoinjectors Between 2007 and 2014. <i>JAMA Internal Medicine</i> , 2017, 177, 736.	2.6	7
42	Association of Prescription Drug Price Rebates in Medicare Part D With Patient Out-of-Pocket and Federal Spending. <i>JAMA Internal Medicine</i> , 2017, 177, 1185.	2.6	54
43	Mitigating Financial Toxicity Among US Patients With Cancer. <i>JAMA Oncology</i> , 2017, 3, 765.	3.4	25
44	Effect of FDA Investigation on Opioid Prescribing to Children After Tonsillectomy/Adenoidectomy. <i>Pediatrics</i> , 2017, 140, .	1.0	46
45	Biosimilars: Reimbursement Issues in Your Oncology Practice. <i>Journal of Oncology Practice</i> , 2017, 13, 12s-14s.	2.5	4
46	Policy Diffusion across Disparate Disciplines: Private- and Public-Sector Dynamics Affecting State-Level Adoption of the ACA. <i>Journal of Health Politics, Policy and Law</i> , 2017, 42, 377-385.	0.9	2
47	A Pathway Through the Bundle Jungle. <i>Journal of Oncology Practice</i> , 2016, 12, 504-509.	2.5	16
48	Use of Low-Value Pediatric Services Among the Commercially Insured. <i>Pediatrics</i> , 2016, 138, .	1.0	44
49	THE ADVANTAGES OF AWARDDING THE FEDERAL GOVERNMENT NEGOTIATING POWER OVER THE PRICES OF PRESCRIPTION DRUGS. <i>Journal of Policy Analysis and Management</i> , 2016, 35, 964-970.	1.1	1
50	RESPONSE TO JOYCE AND SOOD. <i>Journal of Policy Analysis and Management</i> , 2016, 35, 972-974.	1.1	0
51	Changing the Cost of Care for Chronic Myeloid Leukemia: The Availability of Generic Imatinib in the USA and the EU. <i>Hematologic Malignancies</i> , 2016, , 231-255.	0.2	0
52	21st century pharmacovigilance: efforts, roles, and responsibilities. <i>Lancet Oncology</i> , The, 2016, 17, e486-e492.	5.1	55
53	Pharmaceuticals and Public Health. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 2083.	3.8	4
54	National Economic Conditions and Patient Insurance Status Predict Prostate Cancer Diagnosis Rates and Management Decisions. <i>Journal of Urology</i> , 2016, 195, 1383-1389.	0.2	16

#	ARTICLE	IF	CITATIONS
55	Pharmaceutical Policy Reform â€” Balancing Affordability with Incentives for Innovation. <i>New England Journal of Medicine</i> , 2016, 374, 703-706.	13.9	28
56	<b>Overspending driven by oversized single dose vials of cancer drugs</b>. <i>BMJ, The</i> , 2016, 352, i788.	3.0	109
57	Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw003.	3.0	82
58	Pricing in the Market for Anticancer Drugs. <i>Journal of Economic Perspectives</i> , 2015, 29, 139-162.	2.7	379
59	Reply to M. Thompson et al. <i>Journal of Oncology Practice</i> , 2015, 11, 263-264.	2.5	0
60	How Do Payers Respond to Regulatory Actions? The Case of Bevacizumab. <i>Journal of Oncology Practice</i> , 2015, 11, 313-318.	2.5	5
61	Antidepressant treatment and suicide attempts and selfâ€inlicted injury in children and adolescents. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 208-214.	0.9	21
62	Expanding the Scope of the National Practice Oncology Benchmark Would Be a Critical Source for Understanding Outpatient Oncology Practice Costs and Profits in a Time of Change. <i>Journal of Oncology Practice</i> , 2015, 11, e95-e97.	2.5	3
63	Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU. <i>Annals of Hematology</i> , 2015, 94, 249-257.	0.8	39
64	Reform of the Buy-and-Bill System for Outpatient Chemotherapy Care Is Inevitable: Perspectives from an Economist, a Realpolitik, and an Oncologist. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e75-e80.	1.8	19
65	National Trends In Spending On And Use Of Oral Oncologics, First Quarter 2006 Through Third Quarter 2011. <i>Health Affairs</i> , 2014, 33, 1721-1727.	2.5	50
66	Payment for Oncolytics in the United States: A History of Buy and Bill and Proposals for Reform. <i>Journal of Oncology Practice</i> , 2014, 10, 357-362.	2.5	22
67	Problems With Public Reporting of Cancer Quality Outcomes Data. <i>Journal of Oncology Practice</i> , 2014, 10, 215-218.	2.5	6
68	The 340B Drug Discount Program: Hospitals Generate Profits By Expanding To Reach More Affluent Communities. <i>Health Affairs</i> , 2014, 33, 1786-1792.	2.5	51
69	Improving Outpatient Oncology Practice: Several Steps Into a Long Journey. <i>Journal of Oncology Practice</i> , 2014, 10, 355-356.	2.5	0
70	What Is the Most Cost-Effective Strategy for Treating Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) after Imatinib Loses Patent Exclusivity?. <i>Blood</i> , 2014, 124, 738-738.	0.6	6
71	Prevalence of Off-Label Use and Spending in 2010 Among Patent-Protected Chemotherapies in a Population-Based Cohort of Medical Oncologists. <i>Journal of Clinical Oncology</i> , 2013, 31, 1134-1139.	0.8	113
72	Effects of FDA Advisories on the Pharmacologic Treatment of ADHD, 2004â€”2008. <i>Psychiatric Services</i> , 2013, 64, 339-346.	1.1	25

#	ARTICLE	IF	CITATIONS
73	Cost Consequences of the 340B Drug Discount Program. JAMA - Journal of the American Medical Association, 2013, 309, 1995.	3.8	48
74	Drug Discount Programâ€”Reply. JAMA - Journal of the American Medical Association, 2013, 310, 1627.	3.8	0
75	The Impact of Emerging Safety and Effectiveness Evidence on the Use of Physician-administered Drugs. Medical Care, 2013, 51, 622-627.	1.1	11
76	An Analysis Of Whether Higher Health Care Spending In The United States Versus Europe Is â€”Worth Itâ€”™ In The Case Of Cancer. Health Affairs, 2012, 31, 667-675.	2.5	57
77	Trends in Use of Second-Generation Antipsychotics for Treatment of Bipolar Disorder in the United States, 1998â€”2009. Psychiatric Services, 2012, 63, 83-86.	1.1	42
78	Infused Chemotherapy Use in the Elderly After Patent Expiration. Journal of Oncology Practice, 2012, 8, e18s-e23s.	2.5	7
79	Impact of FDA Drug Risk Communications on Health Care Utilization and Health Behaviors. Medical Care, 2012, 50, 466-478.	1.1	185
80	Trends in Attention Deficit Hyperactivity Disorder Ambulatory Diagnosis and Medical Treatment in the United States, 2000â€”2010. Academic Pediatrics, 2012, 12, 110-116.	1.0	74
81	Changes in antipsychotic use among patients with severe mental illness after a Food and Drug Administration advisory. Pharmacoepidemiology and Drug Safety, 2012, 21, 1251-1260.	0.9	8
82	Infused chemotherapy use in the elderly after patent expiration. American Journal of Managed Care, 2012, 18, e173-8.	0.8	5
83	Overuse of Antidepressants in a Nationally Representative Adult Patient Population in 2005. Psychiatric Services, 2011, 62, 720-726.	1.1	18
84	Racial and ethnic disparities in cardiovascular medication use among older adults in the United States. Pharmacoepidemiology and Drug Safety, 2010, 19, 834-842.	0.9	58
85	Impact of FDA Black Box Advisory on Antipsychotic Medication Use. Archives of Internal Medicine, 2010, 170, 96.	4.3	211
86	Personalized Medicine and Genomics: Challenges and Opportunities in Assessing Effectiveness, Cost-Effectiveness, and Future Research Priorities. Medical Decision Making, 2010, 30, 328-340.	1.2	99
87	The Economics of Comparative Effectiveness Studies. Pharmacoeconomics, 2010, 28, 843-853.	1.7	25
88	Value of research analysis: an application to drug development. Clinical Advances in Hematology and Oncology, 2009, 7, 298-300.	0.3	0
89	Nonprofit Biomedical Companies. Clinical Pharmacology and Therapeutics, 2008, 84, 194-197.	2.3	5
90	Use of Prescription and Over-the-counter Medications and Dietary Supplements Among Older Adults in the United States. JAMA - Journal of the American Medical Association, 2008, 300, 2867.	3.8	809

#	ARTICLE	IF	CITATIONS
91	The societal benefit of nonprofit biotechnology companies. <i>Clinical Advances in Hematology and Oncology</i> , 2008, 6, 366-7, 386.	0.3	1
92	A pediatric-focused review of the performance incentive literature. <i>Current Opinion in Pediatrics</i> , 2007, 19, 719-725.	1.0	22
93	Using Performance Data to Identify Preferred Hospitals. <i>Health Services Research</i> , 2007, 42, 2109-2119.	1.0	15
94	Mental Health Policy and Psychotropic Drugs. <i>Milbank Quarterly</i> , 2005, 83, 271-298.	2.1	65
95	Racial Disparities in Access to Renal Transplantation â€” Clinically Appropriate or Due to Underuse or Overuse?. <i>New England Journal of Medicine</i> , 2000, 343, 1537-1544.	13.9	531
96	Out-of-Pocket Spending on Epinephrine Auto-Injectors Among the Privately Insured, 2015â€”2019. <i>Journal of General Internal Medicine</i> , 0, , .	1.3	0